Krystal Biotech, Inc. (KRYS) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 9.69B USD. 52-week range 179.19 to 382.54 USD. Trailing P/E 41.0. Data as of 2026-10-09.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical ...